loader
Please Wait
Applying Filters...

Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of Drug Master Files (DMF) for 28209 Active Pharmaceutical Ingredient (API) submitted to the U.S. FDA. Original Data : FDA Website

    Client Virtual Booth
    Menu

    Clarochem Ireland

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Aspen API. More than just an API.

    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 Clarochem Ireland (1)

    filter

    01 CL1109 (1)

    filter

    01 Ireland (1)

    filter

    01 Active (1)

    filter

    01 Complete (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us

    CLAROCHEM IRELAND LTD

    Contact Supplier
    • FDA
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag Ireland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    CL1109

    PDF Supplier PDF
    URL Supplier Web Content
    28209
    Active
    2014-05-23
    Complete
    2014-06-11
    2014-05-13
    II
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    Looking for Drug Master Files (DMF) for 28209 of Clarochem Ireland Ltd

    Looking for Drug Master Files (DMF) for 28209 of Clarochem Ireland Ltd 1

    20

    Clarochem Ireland Ltd, based in Ireland, is a pharmaceutical company that stands out with its certifications from FDA.

    One of their notable products is CL1109, with a corresponding US DMF Number 28209.

    Remarkably, this DMF maintains an Active status since its submission on May 23, 2014, highlighting commitment to regulatory compliance.

    Their GDUFA DMF Review was successfully complete, with a review date of June 11, 2014, and payment made on May 13, 2014, indicating their dedication to facilitating drug approvals, Categorized as Type II

    Post Enquiry
    POST ENQUIRY